Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
O-antigen polysaccharide and Vi capsular polysaccharide are major surface carbohydrate antigens of Salmonella species, functioning as critical immune targets and virulence factors. The O-antigen polysaccharide forms the serotype-defining outer part of lipopolysaccharide (LPS), composed of repeating oligosaccharide units with high structural variability that determine immunogenic specificity and resistance to host complement-mediated killing[1][5][7]. Vi capsular polysaccharide, present in Salmonella Typhi and Paratyphi C, is a distinct extracellular capsule that shields surface antigens and is a major target of protective antibodies in typhoid vaccines[1][6]. Both antigens are exploited in vaccine strategies—either as purified polysaccharides or conjugated to carrier proteins—to stimulate production of anti-Salmonella antibodies that mediate protection via opsonization, complement activation, and immune memory[6][7]. Variability in O-antigen structure among Salmonella serovars and the limited immunogenicity of unconjugated polysaccharides present challenges for vaccine development[8][1]. These bacterial polysaccharide antigens are not conventional receptors or enzymes but are validated immunological targets for prophylactic (vaccine) interventions. **Note:** This entry is marked as **is_incorrect: true** because it describes not a single molecule/receptor, but an immunological concept (antibody production targeting two different polysaccharide antigens), and includes more than one canonical target; structured information requires treatment as two entities or as a vaccine concept, not a discrete molecular target[1][6][7].
Antibodies targeting these antigens mediate opsonization and phagocytosis, promote complement-mediated bactericidal activity, prevent bacterial attachment/invasion, and establish immunological memory via an adaptive immune response[4][6][7].
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on O-antigen polysaccharide and Vi capsular polysaccharide of Salmonella (anti-Salmonella antibody targets).